Hit-to-lead
Peptide Hit-to-Lead — From Initial Hit to Nominated Lead
The hit-to-lead phase is where peptide drug discovery programs are won or lost. Converting an initial hit — a sequence with promising but imperfect activity — into a nominated lead with the right combination of potency, selectivity, and developability requires systematic computational and experimental optimization. We support the full hit-to-lead arc for peptide programs.
The Hit-to-Lead Challenge
Initial peptide hits from screening or rational design rarely have the combination of potency, selectivity, stability, and developability required for a drug candidate. The hit-to-lead phase must systematically address each of these dimensions while maintaining the activity that made the hit interesting in the first place.
Computational methods that model structure-activity relationships, predict developability liabilities, and guide systematic sequence optimization can dramatically reduce the number of synthesis-test cycles required to nominate a lead — compressing timelines and reducing costs.
Our Hit-to-Lead Approach
Hit characterization and SAR analysis
Computational analysis of the initial hit to establish structure-activity relationships and identify key pharmacophore elements.
Hit expansion and analog design
AI-assisted generation of hit analogs that systematically explore sequence space around the initial hit to improve potency and selectivity.
Developability profiling
Early assessment of stability, solubility, and other developability parameters to identify and address liabilities before lead nomination.
Lead nomination criteria
Definition and computational assessment of lead nomination criteria — potency, selectivity, stability, and developability thresholds.
Hit-to-Lead Workflow
Hit characterization
Computational analysis of the initial hit: binding mode, SAR, and developability profile.
Analog library design
AI-assisted generation of hit analogs targeting potency, selectivity, and stability improvements.
Property prediction
Prediction of activity, selectivity, stability, solubility, and other developability parameters for each analog.
Candidate prioritization
Selection of priority analogs for synthesis and experimental testing based on predicted profiles.
Experimental feedback integration
Integration of experimental data to refine SAR models and guide the next design cycle.
Lead nomination
Final assessment of candidates against lead nomination criteria and selection of the nominated lead.
What Can Be Evaluated
What You May Receive
Hit analog library
Designed analogs with predicted activity, selectivity, and developability profiles.
SAR analysis report
Computational SAR analysis identifying key pharmacophore elements and optimization vectors.
Developability assessment
Predicted stability, solubility, and other developability parameters for priority candidates.
Lead nomination recommendation
Assessment of candidates against lead nomination criteria with a recommended lead.
Deliverables depend on project scope and hit characteristics. Activity and developability outcomes cannot be guaranteed computationally.
Who This Is For
Drug discovery teams
Programs with an initial peptide hit that need systematic computational support to optimize and nominate a lead.
Biotech companies
Companies running peptide drug discovery programs that want to accelerate hit-to-lead with AI-assisted design.
Academic groups
Research groups with a peptide hit from screening or rational design that want to explore the SAR and improve the profile before advancing.
Assess Your Hit Sequence First
Before starting a full hit-to-lead program, use our free tools to characterize your initial hit. The Peptide Property Analyzer provides physicochemical profiling; the Drug-Likeness Predictor flags hemolysis risk, solubility issues, and membrane permeability — key developability liabilities to address early in hit-to-lead.
Frequently Asked Questions
Accelerate Your Peptide Hit-to-Lead Program
Submit your hit sequence, target, and current activity data. We will assess the hit-to-lead opportunity and outline a computational optimization approach for your program.
Confidential project discussions available under NDA.